Clinical Trials Logo

Skin Metastases clinical trials

View clinical trials related to Skin Metastases.

Filter by:
  • None
  • Page 1

NCT ID: NCT01479946 Withdrawn - Breast Cancer Clinical Trials

Electrochemotherapy For The Treatment Of Breast Cancer That Has Spread to the Skin

Start date: October 2011
Phase: Phase 2
Study type: Interventional

Electroporation combined with chemotherapy (ECT) has been shown to be an effective treatment for breast cancer that has spread to skin. In routine clinical practise, ECT is offered to patients when all other treatment options have been exhausted. This study tests the hypothesis that early treatment with ECT may result in improved local control of skin metastases, improved quality of life and reduced health care costs. Patients are randomised to either ECT given as early as possible in the course of the disease or delaying ECT for at least 6 months.

NCT ID: NCT00821964 Completed - Clinical trials for Stage IV Breast Cancer

Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

Start date: December 2008
Phase: Phase 2
Study type: Interventional

This phase II trial is studying the side effects of giving topical imiquimod together with Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) to see how well it works in treating patients with advanced breast cancer. Biological therapies, such as imiquimod, may stimulate the immune system to kill tumor cells. Drugs used in chemotherapy, such as Abraxane, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imiquimod together with Abraxane may kill more tumor cells.

NCT ID: NCT00004074 Completed - Clinical trials for Fallopian Tube Cancer

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Start date: August 1999
Phase: Phase 1
Study type: Interventional

Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Phase I trial to study the effectiveness of interleukin-12 and trastuzumab in treating patients who have cancer that has high levels of HER2/neu and has not responded to previous therapy